COMMUNIQUÉS West-GlobeNewswire

Acentra Health Awarded Five-Year Contract Extension to Continue Utilization Management Services in Colorado
13/08/2026
Contract allows state to promote quality and cost-effective healthcare for 1.3 million Coloradans MCLEAN, Va., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions company dedicated to [...]
Meet Pomoni: Physician-Founded Polyphenol Brand Unveils New Name, New Olive Oil Supplement for Athletes
13/08/2026
Pomoni debuts Phenolia Endurance,Sponsors Iowa City's core4 Gravel Earth Series race BETTENDORF, Iowa, Aug. 13, 2026 (GLOBE NEWSWIRE) -- O-Liv , the physician-founded brand behind HPLC-verified Greek olive polyphenols, [...]
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
13/08/2026
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK [...]
MapLight Therapeutics Announces $150 Million Private Placement Financing
13/08/2026
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating [...]
CurePSP Establishes Public Policy and Advocacy Team to Accelerate National Impact
13/08/2026
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CurePSP has formally established its Public Policy and Advocacy team with the recent additions of Nora Wong, MPH, Associate Director of Public Policy, and Julie Balasalle, MSW [...]
Opción Yo Earns a Place Among the Top 3% of the Inc. 5000
13/08/2026
MIAMI, FL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- — This recognition reflects a profound cultural shift as more people prioritize emotional well-being with the same intention they have long invested in their physical well- [...]
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
13/08/2026
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic [...]
SS Innovations Reports Second Quarter 2026 Financial Results
13/08/2026
Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales FORT LAUDERDALE, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (the “Company” or “SS [...]
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
13/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND ‑ 100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
13/08/2026
Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSide HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. ( [...]
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
13/08/2026
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support Clinical [...]
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA [...]
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
13/08/2026
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - [...]
Collegium Announces $50 Million Accelerated Share Repurchase Program
13/08/2026
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood [...]
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith [...]
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call [...]
Ascendis Pharma Reports Second Quarter 2026 Financial Results
13/08/2026
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ® – Through July 31, more than 220 unique YUVIWEL patient [...]
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
13/08/2026
Q2 2026 Adjusted EBITDA 1 of $0.9M, the Company’s strongest quarterly performance since 2019 2 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 [...]
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
13/08/2026
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, [...]

Pages